e-learning
resources
Vienna 2009
Monday, 14.09.2009
Tuberculosis: metabolism and comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Quantification of long term uptake and metabolism of isoniazid in patients treated for Mycobacterium tuberculosis infection
M. Eisenhut, S. Fieseler, H. Sachs, D. Schmid, D. Thieme (Luton, United Kingdom; Munich, Kreischa, Germany)
Source:
Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Session:
Tuberculosis: metabolism and comorbidities
Session type:
Thematic Poster Session
Number:
2545
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Eisenhut, S. Fieseler, H. Sachs, D. Schmid, D. Thieme (Luton, United Kingdom; Munich, Kreischa, Germany). Quantification of long term uptake and metabolism of isoniazid in patients treated for Mycobacterium tuberculosis infection. Eur Respir J 2009; 34: Suppl. 53, 2545
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Changes in the metabolism of Mycobacterium tuberculosis during the course of TB treatment
Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection
Year: 2021
Hair-analysis for acetyl-isoniazid/isoniazid ratio and N-acetyl-transferase-2-genotype in patients on treatment for mycobacterium tuberculosis infection
Source: Annual Congress 2011 - Tuberculosis: from bench to bedside
Year: 2011
Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
Determination of drug susceptibility of
Mycobacterium tuberculosis
through mycolic acid analysis with HPLC technique - comparison to the conventional methods
Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities
Year: 2005
Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment
Source: Eur Respir J 2003; 21: 478-482
Year: 2003
The peculiarities of drug susceptibility of M. tuberculosis isolated from patients with late-stage HIV infection
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020
Risk factors for Mycobacterium tuberculosis infection among contacts of pulmonary tuberculosis patients
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I
Year: 2012
Different genetics background of patients with latent tuberculosis infection versus active tuberculosis
Source: International Congress 2017 – Asthma genetics and genomics in patients and populations
Year: 2017
Drug resistance of
Mycobacterium tuberculosis
isolated from tuberculosis inflammatory foci
Source: Eur Respir J 2005; 26: Suppl. 49, 654s
Year: 2005
The WHO strategy for TB control and elimination
Source: Eur Respir Mon 2012; 58: 242-253
Year: 2012
Method of treatment of destructive tuberculosis of single lung with extensively drug resistant mycobacteria tuberculosis
Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions
Year: 2011
Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis
Source: Eur Respir J 2007; 30: 321-332
Year: 2007
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary
Mycobacterium avium
complex disease
Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019
Year: 2019
Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population
Source: Eur Respir J 2005; 26: Suppl. 49, 624s
Year: 2005
Detection of isoniazid or rifampin resistant
Mycobacterium tuberculosis
in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay
Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Year: 2005
Pulmonary tuberculosis with primary drug resistant mycobacterium tuberculosis -treatment outcomes
Source: Eur Respir J 2004; 24: Suppl. 48, 657s
Year: 2004
Mycobacterium tuberculosis resistance
Source: Eur Respir J 2002; 20: Suppl. 38, 360s
Year: 2002
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries
Source: Eur Respir J 2015; 46: 1563-1576
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept